# Research Idea Ranking

**Generated:** 2026-01-23T19:49:30.513204
**Model:** gpt-5.2 (reasoning: high)
**Tokens:** 7510
**OpenAI Response ID:** resp_03ecc7674eb4e1a2006973c27694b48197b2f048f04a9229c6

---

### Rankings

**#1: Does Losing Parental Health Insurance at Age 26 Shift Births to Medicaid Coverage? A Regression Discontinuity Design**
- **Score: 74/100**
- **Strengths:** Clean, conceptually sharp design: the age-26 cutoff is salient and hard to manipulate, and natality microdata provides extremely large sample sizes right at the threshold. Outcome (payer at delivery) is directly policy-relevant and measured at the moment of treatment assignment.
- **Concerns:** With public-use natality (age in completed years), the running variable is very discrete, pushing you into weaker/less standard RD inference and potentially wide, design-driven uncertainty. Also need to rule out compositional changes around 26 (pregnancy timing/fertility selection) that could create discontinuities in who gives birth, not just how births are paid for.
- **Novelty Assessment:** **Medium.** Age-26 dependent coverage has a large literature, but *birthday-based RD on delivery payer using natality microdata* is meaningfully less studied than the canonical under-26 vs over-26 DiD outcomes (coverage/employment/utilization).

**Recommendation:** **PURSUE (conditional on: obtaining restricted natality with month/date-of-birth or age-in-months; pre-registering a discrete-RD plan if restricted access fails; explicit density/composition tests around 26).**


---

**#2: Do Prescription Drug Monitoring Program (PDMP) Mandates Reduce Opioid Prescribing? Evidence from Staggered State Adoption**
- **Score: 67/100**
- **Strengths:** Strong policy relevance and rich staggered adoption with many treated states; ARCOS prescribing outcomes are tightly aligned with the mandate mechanism. Large pre-period and many clusters make modern staggered DiD feasible.
- **Concerns:** Endogenous adoption is a first-order threat (states hit hardest may adopt sooner), and the 2012–2019 window is saturated with concurrent opioid policies (pill mill laws, naloxone/GSLs, Medicaid expansion, CDC guidelines), making attribution fragile without a careful policy-bundle strategy. Mortality outcomes are especially hard to interpret because illicit fentanyl dynamics can offset prescription reductions (a “success” on prescribing could coincide with rising deaths).
- **Novelty Assessment:** **Medium–Low.** PDMPs are heavily studied; “mandatory query” + ARCOS + modern staggered DiD is incremental, not transformative.

- **DiD Assessment:**
  - **Pre-treatment periods:** **Strong** (ARCOS 2006+ gives ~6 years pre for early adopters; CDC mortality longer).
  - **Selection into treatment:** **Marginal** (very plausibly adopted in response to worsening opioid trends; must show convincing pre-trend/event-study stability and/or use instruments/stacked DiD around plausibly exogenous shocks).
  - **Comparison group:** **Marginal** (late adopters/not-yet-treated are usable, but may differ systematically in opioid epidemic timing/illicit supply exposure).
  - **Treatment clusters:** **Strong** (≈35+ treated states).
  - **Concurrent policies:** **Marginal** (major overlapping opioid policies + national shocks; needs explicit controls and/or policy-timing exclusion windows).
  - **Outcome-Policy Alignment:** **Strong** (mandatory PDMP query targets prescribing; ARCOS prescribing is the direct margin).
  - **Data-Outcome Timing:** **Marginal** (ARCOS is annual; mandates often effective mid-year → partial exposure in adoption year unless you code exposure fractions or drop/lag the first year).
  - **Outcome Dilution:** **Strong** for prescribing (near-universal exposure); **Marginal** for deaths (multiple channels and substitution dilute interpretability).

**Recommendation:** **CONSIDER (upgrade to PURSUE if: you implement careful timing/exposure coding; explicitly model/adjust for concurrent opioid-policy bundle; separate prescription vs illicit-opioid mortality mechanisms).**


---

**#3: Do State Data Breach Notification Laws Affect Corporate Cybersecurity Investment? Evidence from Staggered Adoption (2002-2018)**
- **Score: 58/100**
- **Strengths:** Long staggered rollout across all states with many treated units and ample pre-period for early adopters. The question is policy-relevant and less saturated than many healthcare designs.
- **Concerns:** The “breach incidence” outcome is mechanically contaminated: laws change *reporting*, not just underlying breaches—so sign and interpretation are ambiguous. “Cybersecurity investment” proxied by state employment of information security analysts is noisy and may reflect broader tech-industry growth, outsourcing, or occupational reclassification rather than within-firm security investment.
- **Novelty Assessment:** **Medium.** There is prior work on breach laws and breaches; the “investment/workforce” angle is less studied, but the proxy/outcome validity is a major limitation.

- **DiD Assessment:**
  - **Pre-treatment periods:** **Strong** (many pre-years before early adopters like CA).
  - **Selection into treatment:** **Marginal** (early adoption correlated with tech intensity, consumer protection preferences; may correlate with pre-trends in cyber labor demand).
  - **Comparison group:** **Marginal** (eventually-treated design helps, but early vs late adopters differ structurally—CA vs AL/SD).
  - **Treatment clusters:** **Strong** (50 states; good for inference).
  - **Concurrent policies:** **Strong–Marginal** (few direct federal equivalents, but many contemporaneous privacy/consumer-protection shifts and tech booms; may matter).
  - **Outcome-Policy Alignment:** **Marginal** (notification laws plausibly induce prevention, but state-level InfoSec employment is an imperfect proxy for firm investment).
  - **Data-Outcome Timing:** **Marginal** (OES employment is tied to a reference period (typically spring); if laws take effect mid/late year, “treated year” may be partial/no exposure unless aligned carefully).
  - **Outcome Dilution:** **Marginal** (if effects concentrate in a subset of firms/industries, state-level occupational employment may dilute effects, especially in low-tech states).

**Recommendation:** **CONSIDER (conditional on: a clearer investment measure—e.g., firm-level security spend, security job postings, cyber insurance uptake; and an explicit strategy to separate reporting effects from true breach changes).**


---

**#4: Do State Dental Therapy Laws Improve Oral Health Care Access? Evidence from Staggered Adoption**
- **Score: 45/100**
- **Strengths:** High topical novelty and clear policy interest (access, rural care, Medicaid spending). Many never-treated states exist for comparison, and BRFSS offers long pre-periods.
- **Concerns:** This proposal fails a key DiD criterion as written: authorization laws do not translate quickly into meaningful population exposure because training pipelines, scope-of-practice limits, and actual deployment are slow and geographically concentrated—so statewide BRFSS utilization is likely severely diluted for many years. ED visit outcomes are also hard to execute credibly without consistent multi-state administrative ED data access.
- **Novelty Assessment:** **High.** Causal evidence on state dental therapy authorization is thin.

- **DiD Assessment:**
  - **Pre-treatment periods:** **Strong** (BRFSS goes back decades).
  - **Selection into treatment:** **Marginal** (adoption likely responds to provider shortages/access problems—i.e., outcome-related trends).
  - **Comparison group:** **Strong** (many never-treated states).
  - **Treatment clusters:** **Marginal** (~14 states; inference and heterogeneity become fragile).
  - **Concurrent policies:** **Marginal** (Medicaid dental benefits, scope-of-practice changes for hygienists, broader Medicaid expansions could coincide).
  - **Outcome-Policy Alignment:** **Strong** in concept (policy aims to increase access/utilization), **but** only if therapists actually enter practice at scale.
  - **Data-Outcome Timing:** **Marginal** (BRFSS dental visit is “past 12 months,” so the first treated survey-year is mechanically part pre-treatment depending on effective dates).
  - **Outcome Dilution:** **Weak (dealbreaker as proposed)** (in early years, dental therapists likely affect a small share of residents—often concentrated in underserved/rural/tribal areas—very plausibly **<10%** of the statewide BRFSS sample).

**Recommendation:** **SKIP (unless redesigned around higher-exposure populations and better outcomes—e.g., Medicaid claims in targeted regions, safety-net clinic utilization, or county-level rollout where therapists are actually deployed).**


---

### Summary

The strongest idea is the **age-26 RD on natality payer**, because the identification is inherently clean and the outcome is tightly linked to the policy margin. The **PDMP mandate DiD** is feasible and policy-relevant but sits in a crowded literature and faces serious confounding from concurrent opioid policies and national shocks. The **dental therapy DiD** should be deprioritized as written due to **weak outcome dilution/timing**, while the **data breach law DiD** is promising only if the team can substantially improve outcome validity beyond mechanically confounded breach counts and coarse employment proxies.